T 细胞急性淋巴细胞白血病治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按治疗类型、最终用户和地理位置细分

市场快照

T-cell acute lymphoblastic leukaemia market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: North America
Largest Market: Asia Pacific
CAGR: 7.8 %
T-cell acute lymphoblastic leukaemia market size

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

  • 导致 T 细胞急性淋巴细胞白血病市场增长的主要因素是全球 T 细胞急性淋巴细胞白血病患病率的上升。
  • 根据美国临床肿瘤学会 (ASCO) 的研究,T 细胞急性淋巴细胞白血病治疗估计占所有急性淋巴细胞白血病的 15% 至 20%。每年记录的新病例数约为每 100,000 名男性和女性中的 1.7 例。美国癌症研究所估计,2019 年约有 5,930 例新的 ALL 病例,即男性 3,280 例,女性 2,650 例。
  • 此外,癌症疗法研发支出的增长、医疗保健支出的增加以及新药开发的创新也推动了全球 T 细胞急性淋巴细胞白血病市场的增长。
  • 然而,对 T-ALL 药物批准的严格规定、高昂的治疗成本以及与治疗相关的不良反应是可能阻碍市场增长的因素。

报告范围

根据范围,T 细胞急性淋巴细胞白血病 (T-ALL) 是一种特定类型的白血病。它是急性淋巴细胞白血病 (ALL) 的一种变体,其特征类似于某些类型的淋巴瘤。它影响产生淋巴细胞的干细胞,特别是一种称为 T 淋巴细胞的白细胞,而 ALL 通常影响 B 淋巴细胞。 

By Type of Therapy
Chemotherapy
Radiation therapy
Stem cell transplant
Others
By End User
Hospitals
Cancer and Radiation Therapy Centers
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

化疗主导全球 T 细胞急性淋巴细胞白血病治疗市场

  • 美国癌症协会表示,化疗是急性淋巴细胞白血病(ALL)患者的主要治疗方法,分为缓解期、巩固期和维持期三个阶段。化疗药物是细胞杀伤疗法。这些药物杀死癌细胞并阻止它们分裂。
  • 化疗通常作为药物组合给予,对于 T-ALL,总是包括类固醇。T-ALL 细胞存在于脑脊髓液 (CSF) 中,因此 T-ALL 的化疗包括向 CSF 中注射。这称为鞘内化疗。这在 T-ALL 中比在其他形式的 ALL 中更常见。
T-cell acute lymphoblastic leukaemia market share

北美主导全球 T 细胞急性淋巴细胞白血病治疗市场

北美在全球 T-ALL 治疗市场占有重要的市场份额,预计在预测期内将保持其地位。T-ALL 的诊断率和患病率在该地区迅速增长。此外,有利的政府政策、完善的医疗保健基础设施以及跨国公司的存在使该地区在这个市场上占据主导地位。

T-cell acute lymphoblastic leukaemia market trends

竞争格局

目前,许多私营公司正专注于新疗法的开发和引进。此外,大多数市场参与者、政府组织和学术研究机构正在开展广泛的研发活动。市场上的一些关键创新包括: 2017 年,西班牙国家癌症研究中心 (CNIO) 的研究人员发现特定基因的基因改变,即 Capicua,已被灭活,至少 10% 直接参与其中儿童最常见的癌症之一,T 细胞急性淋巴细胞白血病。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of T-cell Acute Lymphoblastic Leukemia Market

      2. 4.2.2 Growing Research and Development Expenditure on Cancer Therapeutics

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Scenario for the Drug Approvals

      2. 4.3.2 High Cost Asscoiated with the Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type of Therapy

      1. 5.1.1 Chemotherapy

      2. 5.1.2 Radiation therapy

      3. 5.1.3 Stem cell transplant

      4. 5.1.4 Others

    2. 5.2 By End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Cancer and Radiation Therapy Centers

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bristol Myer Squibb Company

      2. 6.1.2 Celegene Corporation

      3. 6.1.3 Kyowa Kirin Co., Ltd.

      4. 6.1.4 Erytech Pharma

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 Genmab AS

      7. 6.1.7 GlaxoSmithKline

      8. 6.1.8 Novartis AG

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 Spectrum Pharmaceuticals

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The T-cell Acute Lymphoblastic Leukemia Treatment Market market is studied from 2018 - 2026.

The T-cell Acute Lymphoblastic Leukemia Treatment Market is growing at a CAGR of 7.8% over the next 5 years.

North America is growing at the highest CAGR over 2021- 2026.

Asia Pacific holds highest share in 2021.

Bristol Myer Squibb Company, Genmab A/S, Novartis AG, Pfizer Inc., Kyowa Kirin Co., Ltd. are the major companies operating in T-cell Acute Lymphoblastic Leukemia Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!